Educational scope notice: This is a study note for medical students, not medical advice, diagnosis, or treatment guidance. Clinical management should follow local protocols and current guidelines.
Dermatomyositis pairs proximal symmetric weakness with a distinctive skin rash, a combination no other acquired myopathy offers. The rash often brings the patient to attention first, sometimes through dermatology rather than neurology, and it anchors the diagnosis even when serology or biopsy is inconclusive. The disease affects children as well as adults, carries a real association with underlying malignancy in adult onset, and, unlike inclusion body myositis, usually answers to immunosuppression started before atrophy becomes fixed.
The mechanism explains the pathology. Dermatomyositis is a complement-mediated microangiopathy of muscle capillaries rather than a direct T-cell assault on fibres. Ischaemia bites hardest at the watershed zones farthest from supply, which is why atrophy concentrates at fascicle edges, and the same small-vessel injury produces the skin disease. Polymyositis, by contrast, invades fibres directly, which is why it shows endomysial infiltrates and no rash.
Subtypes and serology
Classic disease combines rash with weakness. Amyopathic disease shows the rash without demonstrable muscle involvement in a minority of patients and is still dermatomyositis. Paraneoplastic disease accompanies an underlying cancer, more often in older adults, and overlap syndromes join connective tissue diseases identified by extractable nuclear antigen antibodies. Juvenile disease shares the mechanism but calcifies far more often than adult disease.
Antibodies refine the picture. Anti-Mi-2 tracks with classic skin disease and a good steroid response. Anti-Jo-1 defines the anti-synthetase syndrome, where interstitial lung disease can dominate and threaten life. Serotype-based classification, formalised in the 2017 EULAR/ACR criteria, increasingly guides expectations about organs and course, and the inflammatory myopathy companion sets out the full spectrum.
How dermatomyositis differs from its mimics
| Feature | Dermatomyositis | Polymyositis | Inclusion body myositis |
|---|---|---|---|
| Rash | Present in the large majority | Absent | Absent |
| Weakness pattern | Proximal, symmetric, legs more than arms | Proximal, symmetric | Finger flexors plus quadriceps, sometimes asymmetric |
| Onset | Any age, with a childhood peak | Middle adulthood | Over 50 years |
| Sex pattern | Female-predominant | Female-predominant, less marked | Male-predominant |
| CK | Markedly raised in active disease | Markedly raised | Normal or mildly raised |
| Biopsy hallmark | Perifascicular atrophy | Endomysial cytotoxic invasion | Rimmed vacuoles |
| Calcinosis | Common in juvenile disease, rare in adults | None | None |
| Cancer association | Strong in adult onset | Moderate | None |
| Treatment response | Good | Good | None to immunotherapy |
Three rules carry most bedside decisions. A rash with proximal weakness means dermatomyositis until proven otherwise. Finger-flexor weakness in an older patient unmoved by steroids means inclusion body myositis. New adult-onset dermatomyositis mandates age-appropriate cancer screening at diagnosis and again if disease resists treatment or recurs.
Choose a route through the topic
- Clinical Presentation: demographics, weakness and bulbar patterns, the skin signs, calcinosis, cancer association, and amyopathic disease.
- Diagnosis: enzymes and antibodies, the biopsy hallmark with its caveats, and the screening sequence.
- Treatment: the steroid-led protocol shared with polymyositis, immunoglobulin rescue, refractory options, and malignancy co-management.
Start with the presentation if the rash is unfamiliar, then diagnosis, then treatment in order. The inflammatory myopathy companion holds the family comparison, and the polymyositis and inclusion body myositis notes carry the two differentials in full.
Evidence anchors
- Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734-1747. doi:10.1056/NEJMra1402225
- Lundberg IE, Tjarnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271-2282. doi:10.1002/art.40322